Patents by Inventor Sheila P. Little

Sheila P. Little has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6093397
    Abstract: This invention describe a novel human amyloid precursor protein protease; nucleic acids encoding the protease; and methods employing the protease, as well as methods employing the nucleic acids encoding the protease.
    Type: Grant
    Filed: October 2, 1997
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Eric P Dixon, Edward M. Johnstone, Sheila P. Little
  • Patent number: 5733768
    Abstract: This invention provides an APP-cleaving protein and related nucleic acid compounds. The invention also provides methods, materials and assays. The compounds of this invention will further the characterization of neurological diseases such as Alzheimer's disease and Down's syndrome.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: March 31, 1998
    Assignee: Eli Lilly and Company
    Inventors: Eric P. Dixon, Edward M. Johnstone, Sheila P. Little, Franklin H. Norris
  • Patent number: 5270040
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce subfragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: July 1, 1992
    Date of Patent: December 14, 1993
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. R. Jaskunas, Mei-Huei T. Lai, Sheila P. Little, George L. Long, Robert F. Santerre
  • Patent number: 5244806
    Abstract: The invention discloses modified forms of the enzyme tissue plasminogen activator (t-PA) in which recombinant DNA techniques are utilized to modify the structure of the t-PA cDNA to express a modified t-PA which retains the ability to activate plasminogen yet binds less efficiently to plasmin inhibitor. The invention provides novel DNA compounds and recombinant DNA expression vectors that encode modified human t-PA wherein all or a portion of the kringle protein domains of native human t-PA are removed. Both eukaryotic and prokaryotic expression vectors containing the modified t-PA DNA have been constructed and used to transform Chinese hamster ovary cells and Escherichia coli cells.
    Type: Grant
    Filed: November 19, 1990
    Date of Patent: September 14, 1993
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Sheila P. Little, Brigitte E. Schoner, Barbara J. Weigel
  • Patent number: 5151268
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: July 5, 1988
    Date of Patent: September 29, 1992
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. Richard Jaskunas, Mei-Huei T. Lai, Sheila P. Little, George L. Long, Robert F. Santerre